# A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

> **NCT06773208** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Azacitidine (AZC)
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06773208
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06773208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06773208, "A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06773208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*